Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Therapeutics Chief Scientific Officer equity awards: Todd Alfred Carter received 33,000 restricted stock units and a stock option for 154,000 shares of Voyager Therapeutics common stock on February 6, 2026. The RSUs vest over three years and the option, with a $3.68 exercise price, vests monthly over four years, both based on continued service.
Voyager Therapeutics COO & CBO Robin Swartz reported new equity awards in the company. On February 6, 2026, Swartz was granted 45,000 shares of common stock for no cash consideration, issuable under restricted stock units awarded pursuant to the 2025 Stock Incentive Plan. Following this grant, Swartz beneficially owned 214,647 shares of common stock directly.
On the same date, Swartz received a stock option for 210,000 shares of common stock with an exercise price of $3.68 per share, expiring on February 6, 2036. The RSUs vest over three years in annual installments, and the option vests monthly over four years, in each case conditioned on continued service.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported equity awards on February 6, 2026. He received 402,500 stock options with a $3.68 exercise price, expiring on February 6, 2036, vesting monthly over four years, subject to continued service.
He was also awarded 86,250 restricted stock units, vesting in three equal annual installments starting one year after the grant date, also subject to continued service. Following these awards, he beneficially owned 522,181 shares of common stock, including 5,000 shares acquired under the company’s employee stock purchase plan.
Voyager Therapeutics’ Chief Financial Officer Nathan D. Jorgensen reported new equity awards. He received 32,250 shares of common stock for no cash cost, issuable under restricted stock units that vest over three years starting on February 6, 2026, subject to continued service.
He was also granted a stock option to buy 150,500 shares at an exercise price of $3.68 per share. This option vests monthly over four years starting on February 6, 2026. After these grants, he directly beneficially owned 156,084 shares of common stock.
A holder of VYGR common stock filed a notice of proposed sale under Rule 144 for 12,192 shares, to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $46,093.08. The issuer had 55,600,084 shares outstanding. The shares were acquired on 02/09/2026 through restricted stock vesting as compensation from the issuer.
A shareholder in VYGR has filed a notice of proposed sale under Rule 144 for 4,569 common shares through Fidelity Brokerage Services on or about 02/10/2026, to be sold on NASDAQ. The filing shows an aggregate market value of 17598.87 for these shares, compared with 55,600,084 shares of the same class outstanding.
The shares to be sold were acquired on 02/09/2026 via restricted stock vesting from the issuer as compensation, indicating this is a sale of recently vested equity rather than a market purchase.
Voyager Therapeutics has a planned sale of 3,525 shares of its common stock under Rule 144. The shares have an aggregate market value of $13,552.57 and are to be sold through Fidelity Brokerage Services on NASDAQ around 02/10/2026.
The seller acquired these 3,525 common shares on 02/09/2026 through restricted stock vesting as compensation from the issuer. The filing notes that 55,600,084 shares of common stock were outstanding, providing context for the size of this transaction.
Integrated Core Strategies (US) LLC, affiliates of Millennium Management, and Israel A. Englander report significant passive ownership positions in Voyager Therapeutics, Inc. common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 3,338,862 shares, representing 6.0 % of the outstanding common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 3,407,969 shares, or 6.1 % of the class, through entities they oversee. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Voyager, indicating a passive investment intent as of the event date of 01/16/2026.
Voyager Therapeutics, Inc. reported that its SVP and General Counsel, Gregory L. Shiferman, received a grant of stock options for 100,000 shares of common stock on January 6, 2026. The options have an exercise price of $4.02 per share and were issued under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The options vest over four years, with one quarter of the underlying shares vesting on the one-year anniversary of the grant date and the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued employment. Following this grant, he holds 100,000 stock options directly.
Voyager Therapeutics, Inc. officer Gregory L. Shiferman filed an initial ownership report on Form 3 stating that, as of 01/06/2026, he beneficially owns no securities of the company. He is identified as Senior Vice President and General Counsel, and the filing is made by a single reporting person.